Alzheimer's disease (AD), a serious neurodegenerative disease, is pathologically
characterized by synaptic loss and dysfunction. Synaptic vesicle protein 2A (SV2A) is an …

In recent years, the field of neuroimaging dramatically moved forward by means of the
expeditious development of specific radioligands of novel targets. Among these targets, the …

Histological and biochemical analyses in postmortem tissues have demonstrated
neurodegenerative changes in the cerebral cortex in patients with Alzheimer's disease (AD) …

Synaptic vesicle protein 2A (SV2A), which plays an important role in the pathophysiology of
epilepsy, is a unique vesicular protein recognized as a pharmacological target of …

The synaptic vesicle glycoprotein 2 (SV2) family is comprised of three paralogues: SV2A,
SV2B, and SV2C. In vertebrates, SV2s are 12-transmembrane proteins present on every …

Synaptic vesicle proteins 2 (SV2) were discovered in the early 80s, but the clear
demonstration that SV2A is the target of efficacious anti-epileptic drugs from the racetam …

Alzheimer's disease (AD) is the most common neurodegenerative disorder seen in age-
dependent dementia. There is currently no effective treatment for AD, which may be …

Introduction Synapse loss is one of the hallmarks of Alzheimer's disease (AD) and is
associated with cognitive decline. In this study, we tested [18F] SDM-16, a novel …

The function of synaptic vesicle protein 2A (SV2A) has not been clearly identified, although it
has an essential role in normal neurotransmission. Changes in SV2A expression have been …

Background Previous studies have demonstrated that early intervention was the best plan to
inhibit the progression of Alzheimer's disease (AD), which relied on the discovery of early …